Jaguar Animal Health, Inc. Files Eighth Investigational New Animal Drug Application

SAN FRANCISCO--(BUSINESS WIRE)--Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal and other proprietary health products for companion and production animals, announced today that it has submitted its eighth Investigational New Animal Drug application (“INAD”) with the Center for Veterinary Medicine (“CVM”) of the U.S. Food and Drug Administration for the treatment of insulin-resistance and metabolic syndrome in dogs. To begin development of a drug for animal use, a company must first file an INAD with the CVM and schedule discussions with the CVM to determine the types of studies that will be used to support safety, effectiveness and manufacturing.

The most recent drug candidate in Jaguar’s pipeline is being developed for the treatment of obesity-related metabolic dysfunction in dogs, which manifests in altered lipid profiles, insulin resistance and mild hypertension. These metabolic disturbances affect the health of the dogs and could decrease their lifespan. According to a 2012 national survey of veterinarians, approximately 21% of dogs in the U.S. are obese. Obesity is more common in elderly dogs, as well as in neutered dogs.

Help employers find you! Check out all the jobs and post your resume.